Spaces:
Sleeping
Sleeping
Salma Hassan
commited on
Commit
·
280958f
1
Parent(s):
21f77f5
Enhance app.py by adding a title and enabling fill height and width for the Gradio Blocks in the Clinical Trial Matching Chatbot. This change aims to improve the layout and overall user experience.
Browse files
app.py
CHANGED
|
@@ -512,7 +512,10 @@ if __name__ == "__main__":
|
|
| 512 |
["19-year-old pregnant patient, receiving prenatal care at Johns Hopkins Hospital, is 28 weeks gestation and preparing to receive her first mRNA COVID-19 vaccine dose. She has no previous history of COVID-19 and no significant medical history. She meets eligibility criteria and is interested in contributing to research on pregnancy and vaccine-related immune responses."],
|
| 513 |
["A 67-year-old male with relapsed/refractory multiple myeloma presents for enrollment into a post-trial access study. He previously participated in a Pfizer-sponsored parent study evaluating elranatamab, during which he achieved a partial response and remained clinically stable. At the time the parent trial ended, he was continuing on elranatamab with no evidence of disease progression or significant toxicity. He reports no history of psychiatric illness or lab abnormalities, and he wishes to continue treatment through this access program."]
|
| 514 |
],
|
| 515 |
-
example_icons=["💉", "🤰", "🧪"]
|
|
|
|
|
|
|
|
|
|
| 516 |
)
|
| 517 |
gr.HTML("</div>")
|
| 518 |
|
|
|
|
| 512 |
["19-year-old pregnant patient, receiving prenatal care at Johns Hopkins Hospital, is 28 weeks gestation and preparing to receive her first mRNA COVID-19 vaccine dose. She has no previous history of COVID-19 and no significant medical history. She meets eligibility criteria and is interested in contributing to research on pregnancy and vaccine-related immune responses."],
|
| 513 |
["A 67-year-old male with relapsed/refractory multiple myeloma presents for enrollment into a post-trial access study. He previously participated in a Pfizer-sponsored parent study evaluating elranatamab, during which he achieved a partial response and remained clinically stable. At the time the parent trial ended, he was continuing on elranatamab with no evidence of disease progression or significant toxicity. He reports no history of psychiatric illness or lab abnormalities, and he wishes to continue treatment through this access program."]
|
| 514 |
],
|
| 515 |
+
example_icons=["💉", "🤰", "🧪"],
|
| 516 |
+
title="Clinical Trial Matching Chatbot",
|
| 517 |
+
fill_height=True,
|
| 518 |
+
fill_width=True,
|
| 519 |
)
|
| 520 |
gr.HTML("</div>")
|
| 521 |
|